Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
84.00
+0.26 (0.31%)
Dec 24, 2025, 1:00 PM EST - Market closed
Spruce Biosciences Analyst Ratings
Total Analysts
5
Consensus Rating
Buy
Price Target
$191.90
Upside
+128.45%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $283 | Buy | Initiates | $283 | +236.90% | Dec 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $220 | Strong Buy | Initiates | $220 | +161.90% | Dec 22, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $160 | Hold → Buy | Upgrades | $160 | +90.48% | Dec 3, 2025 |
| Citizens | Citizens | Buy Maintains $254 → $259 | Buy | Maintains | $254 → $259 | +208.33% | Nov 11, 2025 |
| JMP Securities | JMP Securities | Hold → Buy Upgrades $254 | Hold → Buy | Upgrades | $254 | +202.38% | Oct 28, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $10 → $160 | Hold | Maintains | $10 → $160 | +90.48% | Oct 21, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $113 → $38 | Hold | Maintains | $113 → $38 | -55.36% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 16, 2024 |
| Guggenheim | Guggenheim | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 12, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades $225 | Buy → Hold | Downgrades | $225 | +167.86% | Dec 11, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $150 → $113 | Hold | Reiterates | $150 → $113 | +33.93% | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $150 | Hold | Reiterates | $150 | +78.57% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 19, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $150 | Hold | Reiterates | $150 | +78.57% | Aug 13, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $300 → $225 | Buy | Maintains | $300 → $225 | +167.86% | Jun 13, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.